Morphic Holding, Inc. Overview
Pro stress-test →Morphic Holding, Inc. was a Waltham-based biotechnology company specializing in oral integrin therapies for serious chronic diseases including inflammatory bowel disease, autoimmune conditions, and fibrotic diseases. The company was acquired by Eli Lilly in (July 2024) for $3.2 billion, making it a strategic addition to Lilly's immunology and gastroenterology pipeline.
Strategic Profile
Pro stress-test →Morphic differentiated itself through its proprietary MInT Platform, which enabled the development of small-molecule oral integrin inhibitors—a novel approach to targeting integrin receptors. The lead candidate, MORF-057, was in Phase 2 development for ulcerative colitis and Crohn's disease, positioning the company as a promising player in the IBD treatment space before acquisition by Eli Lilly.
Competitive Landscape
Pro stress-test →Prior to acquisition, Morphic competed in the oral small-molecule therapeutic space against companies developing integrin-targeted and IBD treatments. The IBD treatment market includes therapies from AbbVie, Johnson & Johnson/Janssen, Gilead, and Roche. Morphic's differentiation centered on its oral integrin platform versus injectable biologic competitors dominating the IBD market.
Industry Context
Morphic Holding, Inc. operates in Biotechnology / Biopharmaceuticals.
Key facts
Headquarters: Waltham, Massachusetts · Employees: 51-200 · Market cap: N/A (acquired)